Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea

키워드

참고문헌 (59)

1. Wingard JR, "Hematopoietic stem celltransplantation: an overview of infection risks and epidemiology", Infect Dis Clin NorthAm, 24, pp.257~272 (2010)
2. RezvaniAR, "Introduction to hematopoietic celltransplantation, In Transplant infections", pp.1~12 (2010), LippincottWilliams & Wilkins
3. Appelbaum FR, "Hematopoietic-cell transplantation at 50", N Engl J Med, 357, pp.1472~1475 (2007)
4. Lee JW, "The activity of hematopoietic stem celltransplantation in Korea", Bone Marrow Transplant, 42(1), pp.S92~S95 (2008)
5. 이동건, "조혈모세포이식 환자에서 흔히 보는 감염", 대한내과학회지, 84(2), pp.158~167 (2013), 대한내과학회
6. Dropulic LK, "Overview of infections in theimmunocompromised host, in Diagnostic microbiology of theimmunocompromised host", pp.3~43 (2009), ASMPress
7. Safdar A, "Infections in patients with hematologicneoplasms and hematopoietic stem cell transplantation:neutropenia, humoral, and splenic defects", Clin InfectDis, 53, pp.798~806 (2011)
8. Socie G, "Late EffectsWorking Party of the European Study Group for Blood andMarrow Transplantation. Nonmalignant late effects after allogeneicstem cell transplantation", Blood, 101, pp.3373~3385 (2003)
9. Chen CS, "Incidence,risk factors and mortality from pneumonia developinglate after hematopoietic stem cell transplantation", Bone Marrow Transplant, 32, pp.515~522 (2003)
10. Bjorklund A, "Risk factors for fatal infectiouscomplications developing late after allogeneic stem celltransplantation", Bone Marrow Transplant, 40, pp.1055~1062 (2007)
11. Seggewiss R, "Immune reconstitution after allogeneictransplantation and expanding options for immunomodulation:an update", Blood, 115, pp.3861~3868 (2010)
12. Tomblyn M, "Center for InternationalBlood and Marrow Research National MarrowDonor program European Blood and MarrowTransplantGroup American Society of Blood and Marrow TransplantationCanadian Blood and Marrow Transplant Group InfectiousDiseases Society of America Society for HealthcareEpidemiology of America Association of MedicalMicrobiology and Infectious Disease Canada Centers forDisease Control and Prevention. Guidelines for preventinginfectious complications among hematopoietic celltransplantation recipients: a global perspective", Biol BloodMarrow Transplant, 15, pp.1143~1238 (2009)
13. Ljungman P, "Center for International Bloodand Marrow Transplant Research National Marrow DonorProgram European Blood and Marrow Transplant GroupAmerican Society of Blood and Marrow TransplantationCanadian Blood and Marrow Transplant Group InfectiousDisease Society of America Society for Healthcare Epidemiologyof America Association of Medical Microbiology andInfectious Diseases Canada Centers for Disease Controland Prevention. Vaccination of hematopoietic cell transplantrecipients", Bone Marrow Transplant, 44, pp.521~526 (2009)
14. Hilgendorf I, "Vaccinationof allogeneic haematopoietic stem cell transplantrecipients: report from the international consensus conferenceon clinical practice in chronic GVHD", Vaccine, 29, pp.2825~2833 (2011), Vaccine
15. Sullivan KM, "Centers for DiseaseControl and Prevention Infectious Diseases Society ofAmerica American Society for Blood and Marrow TransplantationPractice Guidelines and beyond. Preventingopportunistic infections after hematopoietic stem celltransplantation: the Centers for Disease Control and Prevention,Infectious Diseases Society of America, andAmerican Society for Blood and Marrow TransplantationPractice Guidelines and beyond", Hematology Am Soc HematolEduc Program, pp.392~421 (2001)
16. Ljungman P, "InfectiousDiseases Working Party of the European Groupfor Blood and Marrow Transplantation. Vaccination ofstem cell transplant recipients: recommendations of theInfectious Diseases Working Party of the EBMT", BoneMarrow Transplant, 35, pp.737~746 (2005)
17. Styczynski J, "EBMT Paediatric Diseases WorkingParty. Prevention of infectious complications in pediatricHSCT", Bone Marrow Transplant, 42(2), pp.S77~S81 (2008)
18. Ljungman P, "vaccination recommendationswriting group. Update to vaccination guidelines", BiolBlood Marrow Transplant, 16, pp.1608~1609 (2010)
19. Lee DG, "Hematopoietic stem cell transplantation, in Vaccination for adult", pp.380~388 (2012), MIP Press
20. Small TN, "Immunization of hematopoieticstem cell transplant recipients against vaccine-preventablediseases", Expert Rev Clin Immunol, 7, pp.193~203 (2011)
21. Engelhard D, "Ljungman P Infectious Disease WorkingParty of the European Bone Marrow Transplantation (IDWP-EBMT). Early and late invasive pneumococcal infectionfollowing stem cell transplantation: a European BoneMarrow Transplantation survey", Br J Haematol, 117, pp.444~450 (2002)
22. Youssef S, "Streptococcus pneumoniae infection in 47 hematopoieticstem cell transplantation recipients: clinicalcharacteristics of infections and vaccine-breakthrough infections,1989-2005", Medicine (Baltimore), 86, pp.69~77 (2007)
23. Debbache K, "The epidemiology of invasive Streptococcuspneumoniae infections in onco-haematology andhaematopoietic stem cell transplant patients in France. Arethe serotypes covered by the available anti-pneumococcalvaccines", Clin Microbiol Infect, 15, pp.865~868 (2009)
24. Kumar D, "A randomized, double-blind trialof pneumococcal vaccination in adult allogeneic stem celltransplant donors and recipients", Clin Infect Dis, 45, pp.1576~1582 (2007)
25. Kumar D, "McGeer A Toronto Invasive Bacterial DiseasesNetwork. Invasive pneumococcal disease in adult hematopoieticstem cell transplant recipients: a decade of prospectivepopulation-based surveillance", Bone MarrowTransplant, 41, pp.743~747 (2008)
26. 정희진, "우리나라 성인에서 필요한 예방접종", 대한의사협회지, 54(12), pp.1289~1296 (2011), 대한의사협회
27. Cordonnier C, "Infectious Diseases Working Party ofthe European Group for Blood and Marrow Transplantation.Randomized study of early versus late immunizationwith pneumococcal conjugate vaccine after allogeneicstem cell transplantation", Clin Infect Dis, 48, pp.1392~1401 (2009)
28. Cordonnier C, "Immune response to the23-valent polysaccharide pneumococcal vaccine after the7-valent conjugate vaccine in allogeneic stem cell transplantrecipients: results from the EBMT IDWP01 trial", Vaccine, 28, pp.2730~2734 (2010)
29. Nichols WG, "Influenzainfections after hematopoietic stem cell transplantation:risk factors, mortality, and the effect of antiviral therapy", Clin Infect Dis, 39, pp.1300~1306 (2003)
30. Ljungman P, "Infectious Diseases Working Party, EuropeanGroup for Blood and Marrow Transplantation InfectiousComplications Subcommittee, Spanish Group of HaematopoieticStem-cell Transplantation. Outcome of pandemicH1N1 infections in hematopoietic stem cell transplantrecipients", Haematologica, 96, pp.1231~1235 (2011)
31. Engelhard D, "European guidelines for prevention and managementof influenza in hematopoietic stem cell transplantationand leukemia patients: summary of ECIL-4(2011), on behalf of ECIL, a joint venture of EBMT, EORTC,ICHS, and ELN", Transpl Infect Dis, 15, pp.219~232 (2013)
32. Ditschkowski M, "H1N1 in allogeneicstem cell recipients: courses of infection and influenceof vaccination on graft-versus-host disease(GVHD)", Ann Hematol, 90, pp.117~118 (2011)
33. Choi SM, "Differences in clinical outcomes after 2009 influenzaA", H1N1 and seasonal influenza among hematopoietic cell transplant recipients, 2011, pp.117, 5050~5056
34. Kim SH, "Korean Society of Critical Care MedicineH1N1 Collaborative. Corticosteroid treatment in criticallyill patients with pandemic influenza A", H1N1 2009infection: analytic strategy using propensity scores, 2011, pp.183, 1207~1214
35. Espinosa-Aguilar L, "Novel H1N1 influenza in hematopoieticstem cell transplantation recipients: two centers’experiences", Biol Blood Marrow Transplant, 17, pp.566~573 (2011)
36. Machado CM, "The benefits of influenza vaccination afterbone marrow transplantation", Bone Marrow Transplant, 36, pp.897~900 (2005)
37. Ljungman P, "Influenza vaccination in hematopoieticSCT recipients", Bone Marrow Transplant, 42, pp.637~641 (2008)
38. Li Volti S, "Immunestatus and immune response todiphtheria-tetanus andpolio vaccines in allogeneic bone marrow-transplantedthalassemic patients", Bone Marrow Transplant, 14, pp.225~227 (1994)
39. Hewlett EL, "Pertussis-not just for kids", NEngl J Med, 352 (2005)
40. 최정현, "Immunogenicity and Safety of Diphtheria-tetanus Vaccine in Adults", Journal of Korean Medical Science, 25(12), pp.1727~1732 (2010), 대한의학회
41. Škovránková J, "Persistence of humoral immunity to tetanus and diphtheria in hematopoietic stem cell transplant recipients after post-transplant immunization", Pediatr Blood Cancer, 59, pp.908~913 (2012)
42. Parkkali T, "A randomizedstudy on donor immunization with tetanus-diphtheria,Haemophilus influenzae type b and inactivated poliovirusvaccines to improve the recipient responses to the samevaccines after allogeneic bone marrow transplantation", Bone Marrow Transplant, 39, pp.179~188 (2007)
43. Storek J, "Efficacy of donor vaccinationbefore hematopoietic cell transplantation and recipientvaccination both before and early after transplantation", Bone Marrow Transplant, 33, pp.337~346 (2004)
44. Idilman R, "Hepatitis B virus vaccination of recipients and donorsof allogeneic peripheral blood stem cell transplantation", Clin Transplant, 17, pp.438~443 (2003)
45. Idilman R, "Evaluation and management of hepatitisB virus infectionin hematopoietic stem cell transplantation:before and after transplantation", Expert Rev AntiInfect Ther, 9, pp.641~652 (2011)
46. Jaffe D, "Immunogenicity of recombinanthepatitis B vaccine (rHBV) in recipients of unrelated orrelated allogeneic hematopoietic cell (HC) transplants", Blood, 108, pp.2470~2475 (2006)
47. Na BK, , J MedVirol, 70, pp.649~654 (2003)
48. Lee DG, "A fatal case of measles pneumoniacomplicating an adult recipient of hemopoietic stem celltransplantation during the nationwide epidemic in Korea", Int J Infect Dis, 10, pp.410~411 (2006)
49. Yoo JH, "Infectiouscomplications and outcomes after allogeneic hematopoieticstem cell transplantation in Korea", Bone MarrowTransplant, 34, pp.497~504 (2004)
50. Lee DG, "Characteristics of respiratorytract infections in the hematopoietic stem celltransplantation population", Korean J Infect Dis, 33, pp.419~429 (2001)
51. Ljungman P, "Efficacy andsafety of vaccination of marrow transplant recipients witha live attenuated measles, mumps, and rubella vaccine", JInfect Dis, 159, pp.610~615 (1989)
52. Ljungman P, "Measles immunity after allogeneic stem cell transplantationinfluence of donor type, graft type, intensity of conditioning,and graft-versus host disease", Bone MarrowTransplant, 34, pp.589~593 (2004)
53. Lee SH, "Changes in antibody titers of measles, mumps, rubella,and hepatitis B virus after bone marrow transplantation inKorea: a preliminary report", Korean J Infect Dis, 30, pp.558~563 (1998)
54. Machado CM, "Early measles vaccination in bonemarrow transplant recipients", Bone Marrow Transplant, 35, pp.787~791 (2005)
55. "Incidenceand risk of postherpetic neuralgia after varicella zoster virusinfection in hematopoietic cell transplantation recipients:Hokkaido Hematology Study Group", Biol Blood MarrowTransplant, 15, pp.724~729 (2009)
56. Chou JF, "Safety and immunogenicity of the live attenuated varicellavaccine following T replete or T cell-depleted related andunrelated allogeneic hematopoietic cell transplantation(alloHCT)", Biol Blood Marrow Transplant, 17, pp.1708~1713 (2011)
57. Kussmaul SC, "Safety of the live, attenuated varicellavaccine in pediatric recipients of hematopoietic SCTs", Bone Marrow Transplant, 45, pp.1602~1606 (2010)
58. Tedeschi SK, "Time to consider HPV vaccination afterallogeneic stem cell transplantation", Biol Blood MarrowTransplant, 16, pp.1033~1036 (2010)
59. Carraras E, "Risk assessment in haematopoietic stem celltransplantation: the liver as a risk factor", Best Pract ResClin Haematol, 20, pp.231~246 (2007)

관련 논문AI추천